In a statement, Lannett Company (NYSEMKT:LCI) says it has reviewed the civil complaint from the state attorneys general related to alleged price fixing by generic drug makers. Its involvement is limited to one product that it sells and it believes the charges are without merit. It intends to vigorously defend itself in the lawsuit.
Now read: Kitov Pharmaceuticals: An Update »
Try Seeking Alpha PREMIUM for unlimited analysis on LCI